Evidence on the Use of Topical Ciclosporin for Ocular Surface Disease: A Systematic Review and Meta-Analysis.

Background: To identify evidence on the use of topical CsA for ocular surface diseases (OSD).

Methods: A literature search was conducted following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) through June 2023 via Cochrane Central Registries, Clinical Trials Registry, Grey literature and citation searching. Randomised clinical trials (RCTs) in which different concentrations of topical CsA were compared with one another or other topical therapies were included.

Analysis of Ga2 genome structure and activity reveals widespread distribution of functional alleles in modern maize germplasm.

The Ga2 locus controls unilateral cross incompatibility in Zea species. Molecular characterization of this locus indicates that fully functional loci contain two components that function in male and female reproductive tissues, Ga2P and Ga2F respectively. Some Zea mays varieties have been reported to be capable of overcoming the Ga2 reproductive barrier including the widely used inbred line Mo17.

Time to fix the biodiversity leak.

The risk that locally successful nature conservation may be shifting problems elsewhere can no longer be ignored.

The population genetics of convergent adaptation in maize and teosinte is not locally restricted.

What is the genetic architecture of local adaptation and what is the geographic scale over which it operates? We investigated patterns of local and convergent adaptation in five sympatric population pairs of traditionally cultivated maize and its wild relative teosinte ( subsp. ). We found that signatures of local adaptation based on the inference of adaptive fixations and selective sweeps are frequently exclusive to individual populations, more so in teosinte compared to maize.

Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma.

In this phase-2a study (NCT01994382), patients aged ≥18 years with relapsed/refractory peripheral T-cell lymphoma (PTCL; angioimmunoblastic T-cell lymphoma/T follicular helper [AITL/TFH],  = 29); PTCL-not otherwise specified [NOS],  = 11; and Other,  = 25) received 30 mg oral cerdulatinib, a reversible dual inhibitor of spleen tyrosine kinase and Janus kinase, twice daily in 28-day cycles until disease progression or unacceptable toxicity. Overall response rate (ORR) was 36.2% (12 complete responses [CR],9 partial responses [PR], and 14 stable disease); median time to response was 1.